Hematopoietic stem cells (HSCs) are attractive targets for gene therapy, but current gene transfer methodologies are inadequate for efficient HSC transduction and perpetual transgene expression. To improve gene transfer vectors and transduction protocols, it is vital to establish a system to evaluate transgene expression and the long-term behavior of transduced cells in vivo. For this purpose, we constructed a bicistronic retrovirus encoding the human CD24 (as the first cistron) and the enhanced green fluorescent protein (EGFP; as the second cistron). Murine bone marrow cells were transduced with this vector and the transgene expression was monitored along with hematopoietic reconstitution. Stable expression of CD24 and EGFP was demon-
Introduction
In mammalian hematopoiesis, self-renewing hematopoietic stem cells (HSCs) provide all the progenitors of mature erythroid, myelomonocytic, megakaryocytic and lymphoid lineage cells. Since terminally differentiated cells are relatively short-lived except for memory B and T lymphocytes, HSCs are the ultimate target for gene transfer aiming at long-lasting cure of many monogenic diseases, such as hereditary hemoglobinopathies, phagocyte disorders and immune deficiencies, as well as acquired immunodeficiency syndrome and cancer. 1 To date, murine leukemia virus (MLV)-derived retroviral vectors have been most widely studied as vehicles for gene transfer into hematopoietic cells, based on their potential for efficient transduction and integration into the host chromosomes. 2 However, retroviral transduction studies of human and nonhuman primate HSCs with current protocols have been problematic. 3 Gene transfer into these target cells is usually inefficient, presumably due to limiting factors such as the inability of MLV-based retroviruses to integrate into nondividing cells and the paucity of retroviral receptors on the very immature subset of strated in the long-term repopulating cells for at least 6 months, and multi-parameter flow cytometry illustrated expression of both markers in all the lymphohematopoietic lineages examined (B and T lymphoid, erythroid and myeloid). Sustained expression was also shown in the secondary transplants for 6 months, suggesting that selfrenewing HSCs were transduced by this vector. Overall, EGFP-tagged bicistronic retroviruses would provide powerful tools for detailed in vivo analysis of transduced hematopoietic cells, such as transgene expression in conjunction with lineage differentiation. Gene Therapy (2000) 7, 1193-1199.
primate hematopoietic cells. 4, 5 In addition, expression of vector-encoded proteins is often inconsistent and may be down-regulated over time. 6 Host immune responses against vectors, transgene products and transduced cells may further limit actual gene therapy efficacy. 7, 8 Efforts to improve gene transfer into HSCs and expression in their progeny include developing new classes of vectors and optimizing HSC transduction conditions. 2, 9 These investigations largely depend on convenient and reliable means to monitor transduction efficiency and expression level of the transgenes. One strategy to achieve this task is incorporation of a marker into gene transfer vectors, which enables us to identify and possibly enrich transduced HSCs. For this purpose, selectable markers, such as genes for drug resistance, enzymes converting chromogenic substrates, and cell surface antigens, have been widely studied. 10 Among these, genes conferring drug resistance, such as neomycin phosphotransferase gene (neo), usually require prolonged in vitro culture to achieve differential selection, which may affect the repopulating ability of HSCs. Polymerase chain reaction (PCR)-based assay is used to assess transduction efficiency in vivo, 11 but this approach is somewhat indirect. As for cytochemical markers, such as alkaline phosphatase and bacterial ␤-galactosidase, relatively high endogenous enzyme activity in some cell types and the necessity for substrate loading into the cytoplasm have limited their use. 12, 13 Cell surface markers, such as the low affinity nerve growth factor receptor and CD24, have allowed rapid and efficient selection of transduced cells, 8, 14 although they have the potential of eliciting unintended biological effects in vivo, as well as raising antibodies to eliminate gene-modified cells if they express foreign surface antigens.
Recently, the jellyfish Aequorea victoria green fluorescent protein (GFP) has been introduced as an excellent reporter to noninvasively monitor gene expression and protein localization within cells. 15, 16 GFP has an intramolecular chromophore and requires only blue light and oxygen to fluoresce, without the need for substrates, cofactors or additional gene products. Furthermore, vigorous re-engineering of the wild-type GFP gene has identified several variants with higher fluorescence intensity and expression in mammalian cells, one of which is the enhanced GFP (EGFP). 17, 18 Using refined GFP genes, several authors have shown successful identification and selection of gene-modified hematopoietic cells in vitro and in vivo. [19] [20] [21] [22] However, most of these studies analyzed in vivo GFP expression for relatively short periods, and the impact of GFP expression on hematopoietic and immunologic reconstitution has yet to be fully discussed. In this study, we transduced the EGFP and the human CD24 genes into murine hematopoietic cells and tracked their expression in lethally irradiated hosts for extended time periods (at least 6 months), as well as in secondary transplants.
Results

MSCV/CD24-IRES-EGFP retrovirus
The structures of retroviral vectors used in this study are depicted in Figure 1 . These vectors were constructed with MSCV backbone; the original MSCV vectors have the murine phosphoglycerate kinase promoter (PGK)-driven drug resistance markers for convenient selection. 23 In MSCV/EGFP-PGK-Neo, the EGFP gene was inserted into the MSCV2.1 polylinker at 5′ of the PGK-neo cassette (Figure 1, bottom) . In MSCV/CD24-IRES-EGFP, PGK-neo was replaced with the encephalomyocarditis virus (EMCV)-derived internal ribosome entry site (IRES) and the EGFP gene, 24, 25 to avoid possible interference between the proviral long terminal repeat (LTR) and an internal promoter. EMCV-derived IRES enables coordinated expression of multiple proteins from a single mRNA, while some reports have described that IRES-dependent translation was often less efficient than cap-dependent expression. 26 Indeed, most GFP-featuring retroviral vectors reported to date have been monocistronic or contained the GFP marker placed in the first cistron, presumably in order to obtain utmost fluorescence in transduced cells. [19] [20] [21] [22] We asked whether the EGFP gene in the second cistron could generate adequate fluorescence as a selectable marker, while yielding the first cistron (translated in a cap-dependent manner) to a therapeutic gene. In this study, the human CD24 gene was employed as a reporter for the first cistron, of which expression can be conveniently monitored with specific antibodies. As shown in Figure 1 (top), MSCV/CD24-IRES-EGFP bicistronic retrovirus had the CD24 gene translated in a cap-dependent manner, while the EGFP marker was expressed in an IRES-dependent way.
Transient viral supernatants were obtained by transfecting BOSC23 cells with the MSCV/CD24-IRES-EGFP or MSCV/EGFP-PGK-Neo plasmid. The titer of MSCV/CD24-IRES-EGFP was estimated to be 1 × 10 6 colony-forming units/ml by a simplified RNA dot-blot and hybridization assay, 27 standardizing with the MSCV/EGFP-PGK-Neo supernatant, which was also titrated functionally on NIH3T3 cells (see Materials and methods).
In vitro analysis of transduced bone marrow (BM) cells
Primary murine BM cells were transduced by MSCV/CD24-IRES-EGFP retrovirus with a fibronectinassisted infection protocol, as described previously. 28, 29 After 48 h of transduction, expression of CD24 and EGFP in BM cells was evaluated by fluorescence-activated cell sorting (FACS) and immunofluorescence microscopy. 
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+ ) BM cells than FACS, and the reason for this discrepancy is unknown. Possibly, uneven antibody staining and/or a sensitivity difference between these assays (FACS was much more sensitive, and the fluorescence intensity was shown in log-scale) might account for these observations.
Aliquots of the infected BM cells were subjected to clonogenic progenitor assay to evaluate in vitro differentiation. In repeated experiments, transduced and untransduced BM cells generated similar numbers of colonies without significant difference (data not shown). Staining of isolated erythroid and granulocyte colonies with CD24-rhodamine visualized CD24 
Figure 3 Light and immunofluorescence micrographs of murine hematopoietic cells (original magnification, ×500). Cells were stained with Wright-Giemsa dye (panels a, d, g and j), or with an anti-human CD24 antibody plus rhodamine-conjugated secondary antibody for immunofluorescence microscopy to detect EGFP fluorescence (panels b, e, h and k) and CD24 expression (panels c, f, i and l). (a-c) MSCV/CD24-IRES-EGFP-transduced BM. (d-f) Day 12 erythroid colony derived from MSCV/CD24-IRES-EGFP-transduced BM. (g-i) Day 8 granulocyte colony derived from MSCV/CD24-IRES-EGFP-transduced BM. (j-l) PB cells of a primary transplant on day 98.
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These results suggested that CD24/EGFP expression had little, if any, detrimental effect on in vitro colony formation.
Long-term hematopoietic reconstitution with transduced BM To investigate the impact of GFP expression on lymphohematopoietic reconstitution, lethally irradiated Ly5.2-mice were transplanted with MSCV/CD24-IRES-EGFP-infected congenic Ly5.1-BM cells, and expression of CD24 and EGFP in the transplants was monitored for at least 6 months. Two months after bone marrow transplantation (BMT), more than 90% of the host peripheral leukocytes were donor-derived (ie Ly5.1 + ), and thereafter, the donor cells replaced the host hematopoiesis completely (data not shown). Peripheral blood (PB) was periodically drawn from the transplants to enumerate CD24 + /EGFP + cells by flow cytometry, and the frequency of transgene-expressing cells in the Ly5.1 + population was serially plotted. Ly5.1
+ gating was applied to eliminate mature erythrocytes that did not express Ly5.1 or Ly5.2, and left-over recipient leukocytes present in very small numbers. Table 1 summarizes four reconstitution experiments (BMT 1-4), in which a total of 17 mice were followed for 6 months or longer. In general, percentages of CD24
+ cells in the recipient blood moderately decreased in the first 2-3 months after BMT, and thereafter, the mean frequency of CD24 + /EGFP + cells was roughly one half of that in the infused cells. A significant animal-to-animal deviation in CD24 + /EGFP + frequency was observed in BMT 1-3, where initial transduction efficiency was 25% or lower. In BMT 4, with a higher transduction efficiency (41%), the percentages of transgene-expressing cells moved on with less deviation among the recipients (n = 4). Figure 4a shows the timecourse of CD24 + /EGFP + percentage in each animal in BMT 4. In this group, an initial reduction of CD24 + /EGFP + frequency was also observed, but later, the double-positive cells stayed around 20% until 6 months after BMT. We speculate the reason for the initial decline of CD24 + /EGFP + cells was a difference in cycling activity of target cells during ex vivo transduction. That is, committed progenitors were readily transduced by the retroviral vector because of their active proliferation, but these cells would be differentiated and relatively short-lived after transplantation. In contrast, immature stem/ progenitor cells, which later contributed to long-term repopulation, were slowly dividing in ex vivo culture and relatively transduction-resistant.
During observation of the primary transplants, PB samples from the animals were occasionally examined by immunofluorescence microscopy. As shown in Figure 3j l (day 98 after infusion), CD24/EGFP expression was consistently confirmed in granulocytes and lymphocytes. These results indicated that long-term repopulating murine hematopoietic cells were successfully transduced by MSCV/CD24-IRES-EGFP retrovirus, and transgene expression was stable in multilineage cells.
To confirm further that the GFP-tagged retrovirus was capable of transducing murine HSCs, we undertook secondary hematopoietic reconstitution. Fresh BM were obtained from the primary transplants in BMT 4 at 6 months after transplantation, and an aliquot of the cells was infused into lethally irradiated Ly5.2 recipients. Expression of CD24 and EGFP was monitored in the secondary transplants for another 6 months, where a total of 10 animals was tracked following four independent transplantations. Figure 4b shows the time-course of CD24 + /EGFP + frequency in a group of secondary recipients (n = 3). Although these animals shared the same donor BM, the frequencies of transgene-expressing cells varied significantly (10-52% at 6 months after transplantation). A genomic Southern blot detecting the provirus junctional fragments revealed that only one or two stem cell clones contributed to the CD24 + /EGFP + cells in these secondary recipients (data not shown). Thus, the observed difference in transgene-expressing cells among the secondary transplants was likely to result from uneven distribution of the transduced stem cells either in numbers or in repopulating activity. Since very limited numbers of HSC clones are capable of reconstituting murine hematopoiesis, 30 it is conceivable that competition between the transduced and nontransduced stem cell pools might result in significant deviation of CD24 
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+ cells were also found in immature c-Kit + cells (data not shown), which suggested that the transgenes were expressed in both immature and differentiated cells.
Overall, CD24 + /EGFP + cells were detected in all the lymphohematopoietic tissues and the BM subpopulations, although the percentages of the transgene-expressing cells varied among tissues and lineages. These results, together with the time-course study demonstrating stable CD24/EGFP expression in peripheral leukocytes (Figure 4) , suggested that EGFP is a powerful marker in tracking BM-derived multiple lineages and in quantitative analysis of cotransferred gene expression.
Discussion
GFP has emerged as an excellent reporter of gene transfer, and several groups, including our own, have shown successful hematopoietic cell marking. [19] [20] [21] [22] Refined GFP and related autofluorescent molecules would greatly facilitate developing and improving gene transfer strategies by enabling rapid selection of high titer vector producers and genetically modified target cells, as well as providing a powerful system for evaluating transduction efficiency in vivo. To our knowledge, the present study followed the fate of GFP-transduced primary murine hematopoietic cells for the longest period without selection. Previous in vivo studies reported successful GFP marking of hematopoietic cells for relatively short periods, or showed long-term GFP expression with selective pressure. [19] [20] [21] [22] 32 We have demonstrated that murine BM stem/progenitor cells were transducible with MSCV/CD24-IRES-EGFP retrovirus, and their progeny stably expressed the transgenes through serial transplantation. In the reconstituted mice, EGFP marker was expressed in multiple BM-derived lineages, such as B and T lymphoid, myeloid and erythroid cells. Successful identification of erythroid cells expressing EGFP, together with other lineages observed for a longer period, complemented a report by Bagley et al 21 to authenticate the usefulness of GFP as a marker molecule for genetic labeling of hematopoietic cells.
However, the feasibility of using GFP as an in vivo marker has been challenged by several authors reporting its potential cytotoxicity and antigenicity. Massive expression of xenogenic proteins, the jellyfish GFP for instance, may be hazardous to mammalian cells, but this problem can be circumvented by regulating the gene expression appropriately. In terms of hematopoietic differentiation in vivo, Donahue et al 33 reported an early disappearance of EGFP-expressing myeloid cells from transplanted rhesus PB, while transduced lymphocytes remained in measurable levels. In the present study, we observed a sustained expression of EGFP in murine lymphoid, myeloid and erythroid cells. In some mice, more EGFP + cells were observed in lymphoid lineage (particularly thymocytes), but more myeloid cells expressed EGFP than B lymphoid cells in another transplant BM. Thus, it is unlikely that EGFP expression had an overt disadvantage in total or lineage-restricted hematopoiesis at least in mice. Considering the difficulty in obtaining high-level GFP expression in rhesus myeloid cells, it remains to be explored whether there is a speciesdependent susceptibility to GFP, or whether there is a difference in resistance to GFP among cell types.
Another concern in using GFP is its potential immunogenicity. Transduction of foreign molecules into immunocompetent hosts mostly results in development of immune responses against transgene products, and elimination of the marker-expressing cells was observed in some clinical trials. 7, 8 As for GFP, Stripecke et al 34 recently reported cytotoxic T lymphocyte responses against EGFP-expressing tumor cell lines in murine models. However, the situation may be different in HSC gene
Gene Therapy transfer models from the cases where transduced lymphocytes or tumor cells are transplanted into fully immunocompetent hosts. In most murine BM transduction and reconstitution studies, including this report, transduced stem/progenitor cells are infused into myeloablated hosts, where the given cells should recreate a lymphocyte repertoire recognizing the transgene products as 'self'. Sellers et al 35 showed that neo-transduced BM and CD34-enriched PB cells repopulated in myeloablated nonhuman primates, with similar levels to the BM cells transduced with other vectors encoding the human adenosine deaminase or the murine glucocerebrosidase. The idea that immunological tolerance can be induced by repopulation with transduced HSCs should be extensively discussed in various in vivo settings.
Incorporation of the IRES sequences into retrovirus and other vectors has facilitated coexpression of multiple genes in transduced cells, but IRES-dependent translation has sometimes resulted in reduced protein levels. 26 Here, we showed that EGFP marker fluoresced adequately even when the gene was placed as the second cistron. Therefore, one can place a therapeutic gene in the first cistron to be driven by the LTR promoter, which is a desirable configuration in most retroviral vectors to achieve high titers and sustained expression. 36 Providing a simple means for real-time identification of transduced cells, this type of construct would work as a versatile tool to evaluate various vector modifications, such as ciselements which may affect therapeutic gene expression in vivo. We are currently evaluating similar vectors to transduce HSCs from knockout mice mirroring several human hematopoietic disorders.
Materials and methods
Plasmid construction A bicistronic retrovirus vector, MSCV/CD24-IRES-EGFP, was constructed as follows. The EGFP cDNA (PpuMIXhoI) was obtained from pEGFP-1 (Clontech, Palo Alto, CA, USA) by PCR using an upstream primer containing a PpuMI site (5′-ATGGGACCCAAGGGCGAGGAGCTG TTCACC-3′) and a downstream primer containing an XhoI site (5′-CCTCGAGTTACTTGTACAGCTCGTCC ATGC-3′). The fragment was cloned into the PpuMI-XhoI site of pCMV-I, an expression plasmid harboring the EMCV-derived IRES (nucleotides 259-833 of the EMCV-R genome). 24, 25 From the resultant plasmid, pCGI/EGFP, the IRES-EGFP cassette was obtained as an EcoRI-XhoI fragment and inserted into the EcoRI-SalI site of MSCV2.2 retrovirus (MSCV vector was a gift from Dr RG Hawley, University of Toronto, Toronto, Canada) to make MSCV/IRES-EGFP, replacing PGK-neo. 23 The fulllength human CD24 cDNA was obtained from pBCEC (a gift from Dr S Karlsson, University of Lund, Lund, Sweden) as a BamHI-XhoI fragment, 37 and cloned into the BglII-XhoI site of MSCV/IRES-EGFP, resulting in the final construct, MSCV/CD24-IRES-EGFP (Figure 1 ). For titration reference, MSCV/EGFP-PGK-Neo was constructed by inserting the EGFP cDNA (derived from pEGFP-1) into the EcoRI-XhoI site of MSCV2.1 (Figure 1 ).
Cells and animals
NIH3T3 fibroblasts (American Type Culture Collection (ATCC) CRL-1658, Manassas, VA, USA) and BOSC23 ecotropic packaging cells (ATCC CRL-11554) were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum (FCS; Life Technologies, Grand Island, NY, USA). 38 Primary mouse BM cells were cultured in ␣-minimum essential medium containing 20% FCS and appropriate cytokines. Ly5.2 C57BL/6 mice were purchased from Clea Japan (Tokyo, Japan), and Ly5.1 C57BL/6 mouse colonies were maintained in the institutional animal facility (Jichi Medical School, Tochigi, Japan).
Retroviral transduction of murine BM cells and reconstitution of irradiated hosts
MSCV/CD24-IRES-EGFP and MSCV/EGFP-PGK-Neo retroviral supernatants were prepared by transient transfection of BOSC23 cells with the vector plasmids. Transfection was carried out using Lipofectamine reagent (Life Technologies) following the manufacturer's protocol, and the viral supernatants were harvested 2 days after lipofection. 39 MSCV/EGFP-PGK-Neo viral supernatant was titrated by counting G418-resistant NIH3T3 colonies with a standard infection procedure. MSCV/CD24-IRES-EGFP supernatant was titrated by a simplified RNA dot blot method with a radiolabeled EGFP cDNA probe, 27 standardized by the signals of MSCV/EGFP-PGK-Neo supernatant and the serially diluted plasmid controls on the same blot.
Retroviral transduction of BM cells was carried out with a fibronectin-assisted infection protocol. 28, 29 Ly5.1 C57BL/6 mice (8 weeks of age) were injected intraperitoneally with 150 mg/kg 5-fluorouracil (F Hoffmann-La Roche, Basel, Switzerland), and BM cells were obtained 2 days after injection. Low density mononuclear cells were collected using Lympholyte-M (Cedarlane Laboratories, Hornby, Canada) and prestimulated for 2 days with 100 ng/ml recombinant rat stem cell factor (SCF; provided by Amgen, Thousand Oaks, CA, USA) and 100 U/ml recombinant human interleukin-6 (IL-6; provided by Ajinomoto, Kawasaki, Japan). 40 The prestimulated cells were incubated in the fresh viral supernatant or the conditioned medium of untransfected BOSC23 cells ('mock infection') on plates precoated with recombinant human fibronectin fragment CH-296 (RetroNectin; provided by Takara Shuzo, Otsu, Japan) for 2 additional days under the same growth factor condition as for prestimulation. 29 During transduction, supernatant infection was repeated two to five times. The infected cells were recovered using Cell Dissociation Buffer (Life Technologies) and subjected to further characterization.
For long-term hematopoietic reconstitution, Ly5.2 C57BL/6 mice (8 weeks of age) were lethally irradiated (11 Gy;  137 Cs using a Gamma Cell 40; Nordion International, Kanata, Canada) and intravenously given 2-6 × 10 5 transduced Ly5.1 BM cells per animal. 29 For secondary reconstitution, untreated BM cells from the primary recipients were transfused into lethally irradiated Ly5.2 C57BL/6 mice (1-2 × 10 6 cells per animal).
Flow cytometry and immunofluorescence microscopy Flow cytometry was carried out with a FACScan (Becton Dickinson, San Jose, CA, USA). To monitor frequencies of BM cells and their progeny expressing CD24 and EGFP, cells were dual-stained with a PE-conjugated antihuman CD24 antibody (Pharmingen, San Diego, CA, USA) and a biotinylated anti-Ly5.1 antibody plus PE/Cy5-conjugated streptoavidin (DAKO, Glostrup, Denmark). To evaluate lymphohematopoietic differentiation, biotinylated antibodies against murine lineage markers (c-Kit, B220, CD4, CD8, Gr1, Mac1 and TER119; from Pharmingen) were used along with PE/Cy5-streptoavidin. For immunofluorescence microscopy, cells were stained with an anti-human CD24 antibody (Pharmingen) plus rhodamine-conjugated anti-mouse immunoglobulins (DAKO). The stained cells were cytospun and observed using a BX50-FLA fluorescence microscope (Olympus, Tokyo, Japan; original magnification ×500). Subsequently, cells were stained by the Wright-Giemsa method for morphological characterization.
In vitro clonogenic progenitor assay Progenitor assay was carried out using StemPro Methylcellulose Medium (Life Technologies) supplemented with appropriate growth factors. 41 For erythroid lineage, 1 × 10 4 BM cells were inoculated into 1 ml StemPro medium containing 2 U/ml recombinant human erythropoietin (Epo; provided by Chugai Pharmaceuticals, Tokyo, Japan) and 100 ng/ml SCF. For granulocyte lineage, 1 × 10 4 BM cells were incubated in 1 ml StemPro containing 20 ng/ml recombinant human granulocyte colony-stimulating factor (G-CSF; provided by Chugai Pharmaceuticals). For total colony-forming cells, 1 × 10 3 cells were inoculated into 1 ml StemPro containing 100 ng/ml SCF, 100 U/ml IL-6, 2 U/ml Epo, 20 ng/ml G-CSF and 100 U/ml mouse IL-3 (0.5% conditioned medium of C3H10T1/2 cells transfected with an IL-3 expression plasmid). 42, 43 Colonies were counted between days 7 and 14.
